Report Description

Global monkeypox therapeutics market is anticipated to grow with an impressive CAGR during the forecast years on the grounds of rising instances of monkeypox diseases. Sudden outburst of the viral infection among the population mostly in the European and US region is expected to further drive the growth of the global monkeypox therapeutics market in the upcoming five years. In the year 2003, the infection had suddenly created an uproar as it spread very quickly, and the number of patients exceeded over 40 patients in the span of few weeks. Although the disease spread was controlled fairly but the recent outburst of the infection and rapidly increasing instances give a threat for another possible pandemic and the demand for the effective treatment, vaccination, and other rare disease therapeutics support the growth of the global monkeypox therapeutics market in the next five years. Currently, there are no specific treatment or defined pharmaceutical for the disease, but the symptomatic treatment is possible and surge in the demand for the pain and itch relief due to boils and rashes influences the growth of the global monkeypox therapeutics market in the future five years.

Monkeypox is a viral infection that affects like highly communicable disease with a mere touch and use of material being used by the infected patient. The virus belongs to the family of smallpox and the vaccination and drugs used for controlling the smallpox are somewhat effective for the monkeypox diseases too. Although no specific vaccine or treatment drug has yet came into market for commercialization and research are still continued. Patient with compromised immunity, sick with chronic disease, certain skin conditions like eczema, recovering from recent pandemic, and other anti-viral infections are at high risk of contracting the disease.

Increasing Instances of Disease Drive Market Growth

Sudden increase in the instances of monkeypox among the young and adult population has strived sudden growth in the demand for the monkeypox therapeutics, driving the growth of the global monkeypox therapeutics market in the upcoming five years. Usually, the disease has high impact in the African countries, although recent outburst is seen majorly in the European countries and the United States. Globally, as of May 2022, there are 257 confirmed cases of monkeypox, and the uncontrolled spread is rapidly growing.

In the United States, there are by far 10 confirmed cases and the disease has largely affected the adult population in the country. Most of the population are presenting symptoms like fever, body aches, chills and fatigue whereas the severity of the disease may ensure a rash and lesions on the face and hands that can spread to other parts of the body. High degree of the spread and affects on the human lives have threatened the government and are influencing them to treat it like another pandemic after COVID-19. As in if it is not well controlled in time, the disease will affect large populations and severity may lead to death.

Advancing Pharmaceutical Industry Promises Growth

Growing demand for the timely vaccine and potential treatment for the disease may substantiate the growth of the global monkeypox therapeutics market in the future five years. The governments are actively investing in the research and development of the potent vaccine and drugs to control the spread of the disease and treatment for the affected patient. Also, the government is taking initiatives to promote the drug development procedure with genetic engineering tools to provide vaccination in case the virus evolves in due time affecting larger section of the population.

Genomic sequencing for the virus would elaborate on the specific infection causing sequences that may further help in early diagnosis of the viral infection and deduce effective vaccines to be taken by the population with potential threat to the infection in future years. Also, rising expenses over healthcare services by the population further fuels the growing investments as well as the growth of the global monkeypox therapeutics market in the upcoming five years.


Click here to download the sample

Market Segmentation

The global monkeypox therapeutics market segmentation is based on treatment, end user, regional distribution, and competitive landscape. Based on treatment, the market is fragmented into smallpox vaccine, antivirals, and vaccinia immune globulin (VIG). By end user, the market is fragmented into hospitals, specialty clinics, ambulatory surgical centers, and others. The market analysis also studies the regional segmentation, divided among Asia-Pacific region, North American region, European region, South American region, and Middle East & African region.

Company Profile

Chimerix Inc., SIGA Technologies, Inc., Emergent BioSolutions Inc., Bavarian Nordic A/S, Hetero Drugs Limited, Mylan N.V., Piramal Enterprises Limited, Olon S.p.A., Teva Pharmaceutical Industries Limited, CIDIC Company Limited, are enlisted in a partial list of major market players of the global monkeypox therapeutics market.

Attribute

Details

Base Year

2021

Historical Data

2017 – 2020

Estimated Year

2022

Forecast Period

2023 – 2027

Quantitative Units

Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments covered

·         Treatment

·         End User

Regional scope

North America; Europe; Asia Pacific; Middle East & Africa

Country scope

United States, Canada, Australia, Singapore, Germany, France, United Kingdom, Belgium, Netherlands, Sweden, Italy, Spain, Nigeria.

Key companies profiled

Chimerix Inc., SIGA Technologies, Inc., Emergent BioSolutions Inc., Bavarian Nordic A/S, Hetero Drugs Limited, Mylan N.V., Piramal Enterprises Limited, Olon S.p.A., Teva Pharmaceutical Industries Limited, CIDIC Company Limited

Customization scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

 

Report Scope:

In this report, global monkeypox therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Monkeypox Therapeutics Market, By Treatment:
    • Smallpox Vaccine
    • Antivirals
    • Vaccinia Immune Globulin (VIG)
  • Monkeypox Therapeutics Market, By End User:
    • Hospitals
    • Specialty Clinics
    • Ambulatory Surgical Centers
    • Others
  • Monkeypox Therapeutics Market, By Region:
    • North America
      • United States
      • Canada
    • Asia-Pacific
      • Australia
      • Singapore
    • Europe
      • France
      • Germany
      • United Kingdom
      • Belgium
      • Netherlands
      • Sweden
      • Italy
      • Spain
    • Middle East & Africa
      • Nigeria

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global monkeypox therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Monkeypox Therapeutics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

2.    Research Methodology

3.    Executive Summary

4.    Impact of COVID-19 on Global Monkeypox Therapeutics Market

5.    Voice of Customer

5.1.  Commonly Observed Symptoms of Monkeypox

5.2.  Monkeypox Prevalence, By Gender

5.3.  Monkeypox Prevalence, By Age Group

5.4.  Monkeypox Prevalence, By Region

6.    Global Monkeypox Therapeutics Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Treatment (Smallpox Vaccine, Antivirals, Vaccinia Immune Globulin (VIG))

6.2.2.     By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)

6.2.3.     By Company (2021)

6.2.4.     By Region

6.3.  Product Market Map

7.    North America Monkeypox Therapeutics Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Treatment

7.2.2.     By End User

7.2.3.     By Country

7.3.  North America: Country Analysis

7.3.1.     United States Monkeypox Therapeutics Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Treatment

7.3.1.2.2.             By End User

7.3.2.     Canada Monkeypox Therapeutics Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Treatment

7.3.2.2.2.             By End User

8.    Europe Monkeypox Therapeutics Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Treatment

8.2.2.     By End User

8.2.3.     By Country

8.3.  Europe: Country Analysis

8.3.1.     United Kingdom Monkeypox Therapeutics Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Treatment

8.3.1.2.2.             By End User

8.3.2.     Germany Monkeypox Therapeutics Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Treatment

8.3.2.2.2.             By End User

8.3.3.     France Monkeypox Therapeutics Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Treatment

8.3.3.2.2.             By End User

8.3.4.     Belgium Monkeypox Therapeutics Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Treatment

8.3.4.2.2.             By End User

8.3.5.     Netherlands Monkeypox Therapeutics Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Treatment

8.3.5.2.2.             By End User

8.3.6.     Sweden Monkeypox Therapeutics Market Outlook

8.3.6.1.         Market Size & Forecast

8.3.6.1.1.             By Value

8.3.6.2.         Market Share & Forecast

8.3.6.2.1.             By Treatment

8.3.6.2.2.             By End User

8.3.7.     Italy Monkeypox Therapeutics Market Outlook

8.3.7.1.         Market Size & Forecast

8.3.7.1.1.             By Value

8.3.7.2.         Market Share & Forecast

8.3.7.2.1.             By Treatment

8.3.7.2.2.             By End User

8.3.8.     Spain Monkeypox Therapeutics Market Outlook

8.3.8.1.         Market Size & Forecast

8.3.8.1.1.             By Value

8.3.8.2.         Market Share & Forecast

8.3.8.2.1.             By Treatment

8.3.8.2.2.             By End User

9.    Asia-Pacific Monkeypox Therapeutics Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Treatment

9.2.2.     By End User

9.2.3.     By Country

9.3.  Asia-Pacific: Country Analysis

9.3.1.     Australia Monkeypox Therapeutics Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Treatment

9.3.1.2.2.             By End User

9.3.2.     Singapore Monkeypox Therapeutics Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Treatment

9.3.2.2.2.             By End User

10.  Middle East and Africa Monkeypox Therapeutics Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Treatment

10.2.2.  By End User

10.2.3.  By Country

10.3.              MEA: Country Analysis

10.3.1.  Nigeria Monkeypox Therapeutics Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Treatment

10.3.1.2.2.           By End User

11.  Market Dynamics

11.1.              Drivers

11.2.              Challenges

12.  Market Trends & Developments

13.  Competitive Landscape

13.1.              Company Profiles

13.1.1.  Company Details

13.1.2.  Financials (As reported)

13.1.3.  Key Market Focus and Geographical Presence

13.1.4.  Pricing of Target Products

13.1.5.  Market positioning

13.2.              Chimerix Inc.

13.3.              SIGA Technologies, Inc.

13.4.              Emergent BioSolutions Inc.

13.5.              Bavarian Nordic A/S

13.6.              Hetero Drugs Limited

13.7.              Mylan N.V.

13.8.              Piramal Enterprises Limited

13.9.              Olon S.p.A.

13.10.            Teva Pharmaceutical Industries Limited

13.11.            CIDIC Company Limited

14.  Strategic Recommendations

(Note: The companies list can be customized based on the client requirements.)

Figures and Tables

Frequently asked questions

down-arrow

Global monkeypox therapeutics market may grow with impressive CAGR during the forecast period, 2023-2027, on account of higher demands of expanding pharmaceutical industry and growing investment in the biotech-healthcare sector.

down-arrow

Based on treatment, the market is bifurcated into smallpox vaccine, antivirals, and vaccinia immune globulin (VIG). Smallpox vaccines are anticipated to lead the market growth due to similarity in both diseases, and effectiveness of the vaccine over the disease.

down-arrow

Chimerix Inc., SIGA Technologies, Inc., Emergent BioSolutions Inc., Bavarian Nordic A/S, Hetero Drugs Limited, Mylan N.V., Piramal Enterprises Limited, Olon S.p.A., Teva Pharmaceutical Industries Limited, CIDIC Company Limited, among others are some of the leading companies dedicated toward providing related products and services of monkeypox therapeutics and support the future growth of the global monkeypox therapeutics market in the upcoming five years.

down-arrow

New market players may invest actively in research and innovative product development. Also, advancing their existent technology according to evolving consumer preferences along with merger and acquisitions with the global giants can be viable strategic recommendations for the future brand establishments.

profile

Sakshi Bajaal

Business Consultant
Press Release

Monkeypox Therapeutics Market To Grow With Advancing Pharmaceutical Industry

Jun, 2022

Surge in the instances of the infectious diseases supports Global Monkeypox Therapeutics Market growth during the forecast.